Explainer: Where are we in the Covid-19 vaccine race?
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
WEDNESDAY, MAY 18, 2022
WEDNESDAY, MAY 18, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Explainer: Where are we in the Covid-19 vaccine race?

Coronavirus chronicle

Reuters
03 January, 2021, 02:05 pm
Last modified: 03 January, 2021, 02:16 pm

Related News

  • 22 Covid cases reported in 24hrs
  • China Junshi's potential Covid drug shows promise in small trial
  • Indonesia to drop outdoor mask mandate as Covid-19 infections drop
  • N Korean leader slams officials' 'immaturity' in response to Covid outbreak
  • North Korea Covid outbreak is 'worrying' for new variants -WHO

Explainer: Where are we in the Covid-19 vaccine race?

The following is what we know about the race to deliver vaccines to help end the coronavirus pandemic

Reuters
03 January, 2021, 02:05 pm
Last modified: 03 January, 2021, 02:16 pm
Doses of the Pfizer-BioNTech coronavirus disease (Covid-19) vaccine are prepared at the Rene-Muret hospital in Sevran, on the outskirts of Paris, France, December 27, 2020. Thomas Samson/Pool via REUTERS
Doses of the Pfizer-BioNTech coronavirus disease (Covid-19) vaccine are prepared at the Rene-Muret hospital in Sevran, on the outskirts of Paris, France, December 27, 2020. Thomas Samson/Pool via REUTERS

India on Friday became the fourth country to approve a coronavirus vaccine developed by Oxford University and AstraZeneca, authorising the vaccine's rollout in coming weeks in the country with the second highest number of infections.

The following is what we know about the race to deliver vaccines to help end the coronavirus pandemic, which has killed more than 1.8 million people worldwide:

Who Is Fuerthest Along?

US drugmaker Pfizer and German partner BioNTech have been the Covid-19 vaccine trailblazers.

On November 18, they became the first in the world to release full late-stage trial data. Britain was the first to approve the shot for emergency use on December 3, followed by Canada on December 9 and the US Food and Drug Administration (FDA) on December 11. Several other countries, including Saudi Arabia and Mexico, have also approved it.

The European Medicines Agency (EMA) approved the shot on December 21 and India is accelerating its review.

The World Health Organization on Thursday listed the vaccine for emergency use, in a move seeking to speed access to it in the developing world.

What About Moderna?

Moderna Inc was a close second to Pfizer in many countries after it released a full data analysis for a late-stage trial on November 30 showing a 94.1% efficacy rate for its vaccine.

The United States authorised Moderna's vaccine on December 19, while Canada approved the shot on December 23 and the European Medicines Agency (EMA) will do so on January 6.

AstraZeneca

India approval of a two-dose version of AstraZeneca's vaccine, COVISHIELD, which has also been given the green light by Britain, Argentina and El Salvador, is a major win for a shot seen as crucial for mass immunisations.

Questions about the robustness of its trial data have complicated the approval process.

The British company announced interim late-stage trial data in November showing two full doses were 62% effective while a half-dose followed by a full dose had a 90% success rate - but UK regulators the more successful outcome had not stood up to analysis.

AstraZeneca is also in discussions with the European Union's European Medicines Agency, which is conducting a rolling review of the vaccine.

Who Else Is In The Running?

US drugmaker Johnson & Johnson plans to deliver trial data in January, teeing it up for US authorisation in February if its shot is effective. It reduced the enrolment target for its clinical trial to 40,000 volunteers from 60,000 on December 9, potentially speeding results that are tied to how quickly participants become infected.

US firm Novavax is running a late-stage trial in Britain with data due in the first quarter of 2021. It expects to start a large-scale trial in the United States this month.

France's Sanofi and Britain's GlaxoSmithKline, however, announced a setback on December 11 in their attempts to develop a vaccine. The drugmakers said that it showed an insufficient immune response in older people in mid-stage trials and that they would start a new study in February.

What Happens In The Trails?

The companies usually test their vaccines against a placebo - typically saline solution - in healthy volunteers to see whether the rate of Covid-19 infection among those who got the vaccine is significantly lower than in those who received the dummy shot.

How Are Volunteers Infected?

The trials rely on subjects becoming naturally infected with Covid-19, so how long it takes to generate results largely depends on how pervasive the virus is where trials are being conducted. Each drugmaker has targeted a specific number of infections to trigger a first analysis of their data.

How Well Are The Vaccines Supposed To Work?

The World Health Organization ideally wants to see at least 70% efficacy. The FDA wants at least 50% - which means there must be at least twice as many infections among volunteers who received a placebo as among those in the vaccine group. The EMA has said it may accept a lower efficacy level.

What About Russia And China?

Although Pfizer's shot was the first to be rolled out following the publication of full Phase III trial data, Russia and China have been inoculating their citizens for months with several different vaccines still undergoing late-stage trials.

China on December 31. approved its first Covid-19 vaccine for general public use, a shot developed by an affiliate of state-backed pharmaceutical giant Sinopharm. The company said it is 79% effective against the virus.

Russia said on November 24 its Sputnik V vaccine, developed by the Gamaleya Institute, was 91.4% effective based on interim late-stage trial results. It started vaccinations in August and has inoculated more than 100,000 people so far.

India plans to make 300 million doses of Sputnik V next year and Argentina has given the green light for emergency use of the shot, with some 300,000 doses arriving in the country on December 24.

China launched an emergency use programme in July aimed at essential workers and others at high risk of infection. It has vaccinated about one million people as of mid-November using at least three shots - 1 developed by the state-backed China National Biotec Group (CNBG) and one by Sinovac Biotech.

Trial data on a Covid-19 vaccine developed by China's Sinovac Biotech has varied: interim data from a late-stage trial in Turkey showed its CoronaVac shot is 91.25% effective, while researchers in Brazil say the shot was more than 50% effective.

The United Arab Emirates, meanwhile, said on December 9 that one of the CNBG vaccines was 86% effective based on interim results from a late-stage trial in the Gulf Arab state.

Top News

Coronavirus Vaccine / Covid -19 / covid-19 vaccine / Vaccine / Vaccine availability / vaccine data / Vaccine distribution / vaccine doses / Vaccine Diplomacy / Coronavirus Pandemic / Coronavirus / Covid / Covid 19 / Moderna Covid-19 Vaccine / AstraZeneca Covid-19 Vaccine / Pfizer-BioNTech coronavirus vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Sri Lanka default hints at trouble ahead for developing nations
    Sri Lanka default hints at trouble ahead for developing nations
  • Photo: MumitM/TBS
    BERC recommends 57.83% hike in bulk electricity price
  • Central bank cancels foreign trips of its employees
    Central bank cancels foreign trips of its employees

MOST VIEWED

  • Representational image.
    China Junshi's potential Covid drug shows promise in small trial
  • A woman wearing protective mask walks at a sidewalk near business district in Jakarta, Indonesia March 2, 2020. REUTERS/Willy Kurniawan/Files
    Indonesia to drop outdoor mask mandate as Covid-19 infections drop
  • North Korean leader Kim Jong Un presides over a politburo meeting of the ruling Workers' Party, amid the coronavirus disease (COVID-19) pandemic, May 17, 2022, in this photo released May 18, 2022 by North Korea's Korean Central News Agency (KCNA). KCNA via REUTERS
    N Korean leader slams officials' 'immaturity' in response to Covid outbreak
  • North Korea Covid outbreak is 'worrying' for new variants -WHO
    North Korea Covid outbreak is 'worrying' for new variants -WHO
  • People watch a TV broadcasting a news report on the coronavirus disease (Covid-19) outbreak in North Korea, at a railway station in Seoul, South Korea on 17 May 2022. Photo: Reuters.
    N Korea Covid outbreak could have 'devastating' impact on human rights, UN says
  • Two women hug at a closed street during lockdown, amid the coronavirus disease (COVID-19) pandemic, in Shanghai, China, May 16, 2022. REUTERS/Aly Song
    Shanghai achieves 'zero Covid' status but normal life is weeks away

Related News

  • 22 Covid cases reported in 24hrs
  • China Junshi's potential Covid drug shows promise in small trial
  • Indonesia to drop outdoor mask mandate as Covid-19 infections drop
  • N Korean leader slams officials' 'immaturity' in response to Covid outbreak
  • North Korea Covid outbreak is 'worrying' for new variants -WHO

Features

‘The geopolitical landscape is undergoing profound change, Dhaka needs to craft proactive strategies’

‘The geopolitical landscape is undergoing profound change, Dhaka needs to craft proactive strategies’

9h | Interviews
Graphics: TBS

Facebook and Bangladeshi politicians: A new tide in mass political communication?

10h | Panorama
Despite Bangladesh having about 24,000 km of waterways, only a few hundred kilometres are covered by commercial launch services. Photo: Saad Abdullah

Utilising waterways: When common home-goers show the way

1d | Panorama
Illustration: TBS

How Putin revived Nato

1d | Panorama

More Videos from TBS

Bakery business in crisis for increased raw material prices

Bakery business in crisis for increased raw material prices

44m | Videos
Foods that have the most protein

Foods that have the most protein

49m | Videos
How Putin revived Nato

How Putin revived Nato

4h | Videos
Paddle steamers in Bangladesh

Paddle steamers in Bangladesh

9h | Videos

Most Read

1
Representative Photo: Pixabay.
Bangladesh

Microplastics found in 5 local sugar brands

2
Mushfiq Mobarak. Photo: Noor-A-Alam
Panorama

Meet the Yale professor who anchors his research in Bangladesh and scales up interventions globally

3
The story of Bangladesh becoming a major bicycle exporter
Industry

The story of Bangladesh becoming a major bicycle exporter

4
How Bangladesh can achieve edible oil self-sufficiency with local alternatives
Bazaar

How Bangladesh can achieve edible oil self-sufficiency with local alternatives

5
Govt tightens belt to relieve reserve
Economy

Govt tightens belt to relieve reserve

6
Impact of falling taka against US dollar
Banking

Taka losing more value as global currency market volatility persists

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab